Acquisition includes rights to marketing in the European Economic Area, Thailand, South Korea, and other regions for oral treatment of mild to moderately severe dementia associated with Alzheimer disease.
All News
Advertisement
Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.
Advertisement
Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation offers a synopsis of upcoming projects from the Novo Nordisk Foundation.
Advertisement
According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.
The council was established as part of NORD’s Project RDAC.
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation, offers her thoughts on where quantum sensing is heading when it comes to aiding treatment development and clinical studies.
Advertisement
The latest news for pharma industry insiders.
With a final decision expected next February, MenABCWY combines the protective elements of GSK’s existing vaccines to target the five primary serogroups of Neisseria meningitidis.
Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation discusses a recent grant awarded to the Copenhagen Center for Biomedical Quantum Sensing.
BrandShield states that it has identified sites selling counterfeit versions of Wegovy and Ozempic, among other drugs.
The latest news for pharma industry insiders.
Tava’s network of therapists will be added to Health Advocate’s existing network.
The latest news for pharma industry insiders.
Users will be able to access DeepScribe’s documentation platform through AWS.
The latest news for pharma industry insiders.
The program is designed to tackle issues related to the high cost of prescription medication.
Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.
The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.
The latest news for pharma industry insiders.
This facility is the first of four facilities to be built in the area.
New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through a nasogastric tube.
Treatment was initially approved in 2017 for the same indication in children aged 12 and up.
Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas' research and development efforts.
Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and respiratory care devices.
The vaccine is already approved for older adults.